Mayne Pharma Group (FRA:HG6) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HG6 Mayne Pharma Group Ltd FRA:HG6
53 GF Score
Price €1.46
GF Value €2.92
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mayne Pharma Group Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:HG6 vs MCK, CAH, COR: Short Interest Comparison

For the Medical Distribution subindustry, Mayne Pharma Group's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mayne Pharma Group Short Interest vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's Short Interest distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's Short Interest falls into.


FRA:HG6
53GF Score
Mayne Pharma Group Ltd FRA:HG6
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mayne Pharma Group (FRA:HG6) Overvalued in 2026?

Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued. The current stock price of €1.46 is trading 50% below its estimated GF Value™ of €2.92. GuruFocus considers Mayne Pharma Group to be Possible Value Trap.

Key valuation signals for FRA:HG6:

  • Short Interest:
  • GF Value™: €2.92 vs. price of €1.46 (50% below fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the FRA:HG6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mayne Pharma Group Business Description

Other Exchanges MAYNF:USAMYX:Australia
Address 1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
53GF Score

Get the complete analysis for FRA:HG6

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.46
Price
€2.92
GF Value